BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15163180)

  • 21. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combined molecular modeling study on gelatinases and their potent inhibitors.
    Xi L; Du J; Li S; Li J; Liu H; Yao X
    J Comput Chem; 2010 Jan; 31(1):24-42. PubMed ID: 19412908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-O-isopropyl sulfonamido-based hydroxamates: kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors.
    Santamaria S; Nuti E; Cercignani G; Marinelli L; La Pietra V; Novellino E; Rossello A
    Biochem Pharmacol; 2012 Sep; 84(6):813-20. PubMed ID: 22771631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of recombinant mouse collagenase-3 (MMP-13).
    Botos I; Meyer E; Swanson SM; Lemaître V; Eeckhout Y; Meyer EF
    J Mol Biol; 1999 Oct; 292(4):837-44. PubMed ID: 10525409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
    Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
    Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
    Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
    J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Eur J Med Chem; 2008 Oct; 43(10):2130-9. PubMed ID: 18362041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R
    Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.
    Campestre C; Agamennone M; Tortorella P; Preziuso S; Biasone A; Gavuzzo E; Pochetti G; Mazza F; Hiller O; Tschesche H; Consalvi V; Gallina C
    Bioorg Med Chem Lett; 2006 Jan; 16(1):20-4. PubMed ID: 16242329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases.
    Faust A; Waschkau B; Waldeck J; Höltke C; Breyholz HJ; Wagner S; Kopka K; Schober O; Heindel W; Schäfers M; Bremer C
    Bioconjug Chem; 2009 May; 20(5):904-12. PubMed ID: 19374404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
    Nar H; Werle K; Bauer MM; Dollinger H; Jung B
    J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.
    Rubino MT; Agamennone M; Campestre C; Fracchiolla G; Laghezza A; Loiodice F; Nuti E; Rossello A; Tortorella P
    ChemMedChem; 2009 Mar; 4(3):352-62. PubMed ID: 19204958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of matrix metalloproteinases in the onset of dentin mineralization.
    Fanchon S; Bourd K; Septier D; Everts V; Beertsen W; Menashi S; Goldberg M
    Eur J Oral Sci; 2004 Apr; 112(2):171-6. PubMed ID: 15056115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion of potent MMP inhibitors into selective TACE inhibitors.
    Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
    Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E
    Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.
    Pochetti G; Gavuzzo E; Campestre C; Agamennone M; Tortorella P; Consalvi V; Gallina C; Hiller O; Tschesche H; Tucker PA; Mazza F
    J Med Chem; 2006 Feb; 49(3):923-31. PubMed ID: 16451058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.